Abeona Therapeutics to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
DALLAS, TX and NEW YORK, NY -- (Marketwired) -- 02/09/16 -- Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Jeffrey Davis, COO, will be presenting for the company at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference in New York City, NY on Wednesday, February 10th, 2016 at 1:45pm EST on Track 2 in the Murray Hill Hub, along with joining a panel discussion Wednesday, February 10th, 2016 at 3:15pm EST at Convene New York, NY.
Presentation: BIO CEO and Investor Conference
Date: Wednesday, February 10th, 2016
Time: 1:45pm EST
Location: Convene, New York City
Room: Track 2, Murray Hill Hub
Panel Discussion: Immunotherapy Panel
Date: Thursday, February 10th, 2016
Time: 3:15-4pm EST
Location: Track 4 in the Soho Hub
About Source Capital Group
Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client's needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. We have grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to our investment banking activity. http://www.sourcegrp.com/
About Abeona: Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Company and Media Contact:
Andre'a Lucca
VP of Communications
Abeona Therapeutics, Inc.
+1 (212)-786-6208
alucca@abeonatherapeutics.com
Magdalena Tyrpien
Director of Investor Relations
Abeona Therapeutics, Inc.
+1 (212)-786-6209
mtyrpien@abeonatherapeutics.com
Source: Abeona Therapeutics
Released February 9, 2016